F19.27
Other psychoactive substance dependence with psychoactive substance-induced persisting dementia
Clinical Classification Guidelines
Inclusion Terms
- Other (or unknown) substance use disorder, moderate, with other (or unknown) substance induced major neurocognitive disorder
- Other (or unknown) substance use disorder, severe, with other (or unknown) substance induced major neurocognitive disorder
Medical Intelligence & Overview
ICD-10 code F19.27 refers to a condition where an individual is dependent on psychoactive substances—substances that affect the brain and mental processes—and experiences lasting cognitive decline or dementia caused by the substance use. This condition highlights a serious concern where substance dependence is linked with ongoing mental deterioration, affecting the person's ability to think, remember, and function normally. Recognizing and understanding this diagnosis can help in managing the associated health challenges.
Causes & Symptoms
Clinical Causes: Chronic use of psychoactive substances such as opioids, stimulants, sedatives, or hallucinogens over an extended period. Repeated or heavy consumption leading to physical and psychological dependence. Genetic factors that may predispose individuals to substance dependence and cognitive decline. Concurrent mental health disorders or other medical conditions that can exacerbate cognitive impairment. Lack of access to treatment or intervention during early stages of substance use disorder.
Key Symptoms: Memory problems and forgetfulness Difficulty concentrating or paying attention Impaired judgment and decision-making abilities Changes in personality or behavior Impaired daily functioning and independence Confusion or disorientation Speech or language difficulties Reduced motivation or apathy Problems with coordination or motor skills
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves a comprehensive assessment by healthcare professionals, including medical history, physical examinations, and neurocognitive testing. Healthcare providers consider substance use history in conjunction with cognitive assessments to determine if the cognitive impairment is related to psychoactive substance dependence. Laboratory tests, such as blood or urine analyses, may be used to identify the substances involved. Neuroimaging techniques like MRI or CT scans can help rule out other neurological causes of dementia.
Treatment Protocols: Managing this condition typically requires a multidisciplinary approach that includes: - Substance abuse treatment programs focusing on detoxification, counseling, and behavioral therapies. - Cognitive rehabilitation strategies to support memory and functional skills. - Medical management of withdrawal symptoms and comorbid conditions. - Support groups and family counseling to provide emotional and social support. - Long-term monitoring to assess cognitive changes and prevent further decline. Treatment plans are personalized based on the severity of dependence and cognitive impairment, aiming to improve quality of life and functional abilities.
Clinical Advice & FAQs
Billing Guidance
Is F19.27 a billable ICD-10 code?
Yes, F19.27 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report F19.27?
Clinical documentation must specify the nature of Other psychoactive substance dependence with psychoactive substance-induced persisting dementia and any associated comorbidities for accurate reporting.
Cite this Clinical Reference